Thomas Kander
6
2
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger
Role: lead
Autopsy and Photon Counting Computed Tomography to Evaluate Thromboses Related to Central Venous Catheters
Role: lead
Immediate Mechanical Complications After Central Venous Catheterization
Role: lead
Contact Activation of Coagulation in Newly Inserted Central Venous Catheters
Role: lead
Ultrasound-guided Subclavian Vein Catheterisation With a Needle Guide
Role: lead
The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Role: lead
All 6 trials loaded